Table 2.

Six-month pre-index and 12-month post-index clinical characteristics in commercially insured acromegalic individuals, by study cohort

Comorbidities (%)	6-month pre-index period			12-month post-index period
	Medical therapy (N = 169)	Surgical therapy (N = 228)	p value	Medical therapy (N = 169)	Surgical therapy (N = 228)	p value
Local effects
Visual-field defects	0.6	1.8	0.082	3.1	4.8	0.103
Hypopituitarism	5.3	13.6	0.665	4.4	16.2	0.471
Musculoskeletal
Osteoarthritis	7.7	14.2	0.593	9.2	13.6	0.863
Arthropathy/arthralgia/synovitis	12.4	20.1	0.860	11.8	19.3	0.839
Kyphosis and scoliosis	0.0	1.2	0.134	1.3	0.9	0.763
Vertebral fracture	0.0	1.2	0.134	1.3	0.4	0.397
Carpal tunnel syndrome	0.6	2.4	0.127	2.6	4.4	0.281
Myopathy/myalgia	3.6	4.1	0.597	2.6	5.7	0.482
Cardiovascular
Hypertension	23.7	34.3	0.068	32.0	50.4	0.001
Cardiomyopathy	0.6	1.8	0.127	2.6	3.5	0.298
Cardiac hypertrophy	1.2	3.0	0.645	1.8	4.4	0.461
Heart failure	0.0	1.8	0.053	2.2	2.2	0.770
Valvular heart disease	3.0	5.3	0.350	4.8	7.9	0.315
Cardiac dysrhythmia/arrhythmia	3.0	9.5	0.074	7.0	16.7	0.039
Respiratory
Nasal polyps	0.6	1.2	0.831	0.4	2.6	0.310
Sleep apnea (obstructive and central)	7.1	14.2	0.009	15.8	31.6	<0.001
Endocrine/metabolic
Diabetesa	14.8	23.1	0.536	17.1	27.2	0.352
Abnormal glucose	1.8	5.3	0.072	5.3	11.0	0.047
Galactorrhea	1.8	1.2	0.428	0.9	0.4	0.397
Menstrual abnormality	7.1	8.9	0.448	5.3	7.9	0.726
Impaired libido/impotence	1.2	3.6	0.310	2.6	4.0	0.837
Other
Colon polyp	2.4	5.9	0.668	1.8	10.5	0.105
Hyperhidrosis	0.6	0.0	0.196	2.2	2.2	0.053

^aExcluding impaired glucose tolerance